New first-line treatment option for metastatic prostate cancer
Full article:

The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.  

Other clinical trials for people with prostate cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.